ES2138662T3
(es)
|
1993-06-03 |
2000-01-16 |
Therapeutic Antibodies Inc |
Produccion de fragmentos de anticuerpos.
|
GB9501683D0
(en)
|
1995-01-27 |
1995-03-15 |
Glaxo Group Ltd |
Substances and their uses
|
US6214344B1
(en)
|
1995-06-02 |
2001-04-10 |
Genetech, Inc. |
Hepatocyte growth factor receptor antagonists and uses thereof
|
US5646036A
(en)
*
|
1995-06-02 |
1997-07-08 |
Genentech, Inc. |
Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
GB9517538D0
(en)
*
|
1995-08-26 |
1995-10-25 |
Therapeutic Antibodies Inc |
Production and therapeutic combinations, of antibodies
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
SI9720020B
(en)
|
1996-02-09 |
2001-12-31 |
Basf Ag |
Human antibodies that bind human TNF alpha
|
JP2000507829A
(ja)
|
1996-04-01 |
2000-06-27 |
ジェネンテック インコーポレーテッド |
Apo―2liおよびapo―3アポトーシスポリペプチド
|
CA2258153C
(en)
|
1996-07-03 |
2004-08-17 |
Genentech, Inc. |
Hepatocyte growth factor receptor agonists and uses thereof
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US5990281A
(en)
*
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
US6136958A
(en)
*
|
1996-09-30 |
2000-10-24 |
Genentech, Inc. |
Antibodies to vertebrate smoothened proteins
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
WO1998055615A1
(en)
|
1997-06-05 |
1998-12-10 |
The University Of Texas Board Or Regents |
Apaf-1, the ced-4 human homolog, an activator of caspase-3
|
EP1032661A1
(en)
|
1997-06-18 |
2000-09-06 |
Genentech, Inc. |
Apo-2DcR
|
WO1999036535A1
(en)
|
1998-01-15 |
1999-07-22 |
Genentech, Inc. |
Apo-2 ligand
|
CA2328498A1
(en)
|
1998-06-12 |
1999-12-16 |
Genentech, Inc. |
Monoclonal antibodies, cross-reactive antibodies and method for producing the same____________________________________
|
US6927203B1
(en)
|
1999-08-17 |
2005-08-09 |
Purdue Research Foundation |
Treatment of metastatic disease
|
US7192698B1
(en)
|
1999-08-17 |
2007-03-20 |
Purdue Research Foundation |
EphA2 as a diagnostic target for metastatic cancer
|
EP1303293B1
(en)
|
2000-07-27 |
2008-12-03 |
Genentech, Inc. |
Sequential administration of cpt-11 and apo-2l polypeptide
|
US7101976B1
(en)
|
2000-09-12 |
2006-09-05 |
Purdue Research Foundation |
EphA2 monoclonal antibodies and methods of making and using same
|
AU2001296846B2
(en)
|
2000-10-12 |
2007-07-05 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US6709655B2
(en)
*
|
2001-02-28 |
2004-03-23 |
Instituto Bioclon, S.A. De C.V. |
Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
EP2075256A2
(en)
|
2002-01-14 |
2009-07-01 |
William Herman |
Multispecific binding molecules
|
US7811992B2
(en)
|
2002-02-06 |
2010-10-12 |
Stasys Technologies, Inc. |
Anti-infarction molecules
|
US7317087B2
(en)
|
2002-03-25 |
2008-01-08 |
The Uab Research Foundation |
Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
|
CA2489540A1
(en)
|
2002-06-14 |
2003-12-31 |
The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer |
Methods of treating and preventing colitis involving il-13 and nk-t cells
|
CA2495478A1
(en)
|
2002-08-05 |
2004-02-12 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
AU2003293015A1
(en)
|
2002-11-26 |
2004-06-18 |
University Of Utah Research Foundation |
Microporous materials, methods, and articles for localizing and quantifying analytes
|
US7597936B2
(en)
|
2002-11-26 |
2009-10-06 |
University Of Utah Research Foundation |
Method of producing a pigmented composite microporous material
|
US7335759B2
(en)
*
|
2002-12-02 |
2008-02-26 |
Universidad Nacional Autónoma de Méxica (UNAM) |
Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
|
ES2347239T3
(es)
*
|
2002-12-02 |
2010-10-27 |
Amgen Fremont Inc. |
Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
|
US7141015B2
(en)
*
|
2003-05-09 |
2006-11-28 |
Bernard Joseph Ruane |
Expandable and pivotally adjustable surgical retractor
|
MXPA06000965A
(es)
*
|
2003-07-25 |
2007-05-04 |
Silanes Sa De Cv Lab |
Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
US7670771B2
(en)
|
2004-01-21 |
2010-03-02 |
University Of Utah Research Foundation |
Mutant sodium channel Nav1.7 nucleic acid methods
|
RU2429245C2
(ru)
|
2004-03-30 |
2011-09-20 |
Глаксо Груп Лимитед |
Иммуноглобулины
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
AU2005267720B2
(en)
|
2004-08-05 |
2012-02-23 |
Genentech, Inc. |
Humanized anti-cmet antagonists
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
US7381802B2
(en)
*
|
2005-04-15 |
2008-06-03 |
Universidad Nacional Autónoma De México (UNAM) |
Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
|
SG161281A1
(en)
|
2005-04-15 |
2010-05-27 |
Genentech Inc |
Hgf beta chain variants
|
CN101500607B
(zh)
|
2005-05-16 |
2013-11-27 |
阿布维生物技术有限公司 |
TNFα抑制剂治疗腐蚀性多关节炎的用途
|
EP2371843B1
(en)
|
2005-05-19 |
2014-09-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services |
Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
AU2007223427A1
(en)
|
2006-03-01 |
2007-09-13 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
US8470965B2
(en)
|
2006-03-01 |
2013-06-25 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
SG170837A1
(en)
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US9624295B2
(en)
|
2006-04-10 |
2017-04-18 |
Abbvie Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
US20080003230A1
(en)
|
2006-07-03 |
2008-01-03 |
Adair Charles D |
Composition for modulating the expression of cell adhesion molecules
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
WO2008085794A2
(en)
|
2007-01-03 |
2008-07-17 |
Burnham Institute For Medical Research |
Methods and compositions related to clot binding compounds
|
WO2008086002A2
(en)
|
2007-01-08 |
2008-07-17 |
Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Slco1b3 genotype
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
WO2008121437A2
(en)
|
2007-02-08 |
2008-10-09 |
The Burnham Institute For Medical Research |
Trophinin-binding peptides and uses thereof
|
WO2009023306A2
(en)
|
2007-05-09 |
2009-02-19 |
Burnham Institute For Medical Research |
Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
|
WO2008143676A1
(en)
|
2007-05-23 |
2008-11-27 |
The Uab Research Foundation |
Detoxified pneumococcal neuraminidase and uses thereof
|
CN101796197B
(zh)
|
2007-06-08 |
2014-02-12 |
比奥根艾迪克Ma公司 |
预测抗tnf响应性或无响应性的生物标志物
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
PE20090499A1
(es)
|
2007-08-09 |
2009-05-18 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
EP2268664B1
(en)
|
2007-12-03 |
2017-05-24 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Doc1 compositions and methods for treating cancer
|
SG2013054218A
(en)
|
2008-01-15 |
2014-10-30 |
Abbott Gmbh & Co Kg |
Powdered protein compositions and methods of making same
|
HUE024541T2
(hu)
|
2008-05-14 |
2016-01-28 |
Immatics Biotechnologies Gmbh |
Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
|
US8946291B2
(en)
|
2008-08-15 |
2015-02-03 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for treating pigmentary conditions and melanoma
|
EP2328928A2
(en)
|
2008-08-25 |
2011-06-08 |
Dana-Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
ES2536465T3
(es)
|
2008-10-01 |
2015-05-25 |
Immatics Biotechnologies Gmbh |
Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
|
EP2370080A1
(en)
|
2008-12-02 |
2011-10-05 |
University of Utah Research Foundation |
Pde1 as a target therapeutic in heart disease
|
UY32317A
(es)
|
2008-12-12 |
2010-07-30 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
WO2011020107A2
(en)
|
2009-08-14 |
2011-02-17 |
Georgetown University |
Compositions and methods for detection and treatment of breast cancer
|
EP2485768A1
(en)
|
2009-10-07 |
2012-08-15 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding lipid compounds
|
CA2780319A1
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
EP2512497A1
(en)
|
2009-12-18 |
2012-10-24 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding compounds
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
KR20130028055A
(ko)
|
2010-01-28 |
2013-03-18 |
글락소 그룹 리미티드 |
Cd 127 결합 단백질
|
US20110207789A1
(en)
|
2010-02-19 |
2011-08-25 |
Ye Fang |
Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
WO2011141823A2
(en)
|
2010-05-14 |
2011-11-17 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
AU2011267089B2
(en)
|
2010-06-14 |
2017-02-16 |
Lykera Biomed Sa |
S100A4 antibodies and therapeutic uses thereof
|
EP2585145B1
(en)
|
2010-08-19 |
2014-03-05 |
West Pharmaceutical Services, Inc. |
Rigid needle shield
|
US9051619B2
(en)
|
2011-03-25 |
2015-06-09 |
Florida Agricultural and Mechanical University (FAMU) |
Methods and compositions for prostate cancer metastasis
|
AP2013007046A0
(en)
|
2011-03-30 |
2013-08-31 |
Boehringer Ingelheim Int |
Anticoagulant antidotes
|
PL221015B1
(pl)
*
|
2011-04-11 |
2016-02-29 |
Akademia Medyczna Im Piastów Śląskich |
Sposób otrzymywania inhibitorów cysteinowych peptydaz o czystości elektroforetycznej z materiałów biologicznych
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
CA2836898A1
(en)
|
2011-05-20 |
2012-11-29 |
Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services |
Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
CA2850178C
(en)
|
2011-09-30 |
2020-02-25 |
Sarcotein Diagnostics, Llc |
Bin1 expression as a marker of cancer
|
US20130122005A1
(en)
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
WO2013088240A1
(en)
|
2011-12-13 |
2013-06-20 |
Sony Corporation |
Memory device
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
EP2878670B1
(en)
|
2012-06-08 |
2019-08-07 |
Kinki University |
Antibody against transporter and use thereof
|
EP3608401A1
(en)
|
2012-07-05 |
2020-02-12 |
Ohio State Innovation Foundation |
Compositions and methods related to viral vaccines
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
US20140094383A1
(en)
|
2012-10-02 |
2014-04-03 |
Ohio State Innovation Foundation |
Tethered Lipoplex nanoparticle Biochips And Methods Of Use
|
MX367136B
(es)
|
2012-10-18 |
2019-08-06 |
Inosan Biopharma S A Star |
Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
|
WO2014085821A2
(en)
|
2012-11-30 |
2014-06-05 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-met
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9783576B2
(en)
|
2013-06-11 |
2017-10-10 |
Sanford-Burnham Medical Research Institute |
Compositions and methods for targeted endometriosis treatment
|
TWI775117B
(zh)
|
2013-08-05 |
2022-08-21 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(二)
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
EP3069137A1
(en)
|
2013-11-05 |
2016-09-21 |
Novartis Ag |
Organic compounds
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
EP2942627A1
(en)
|
2014-05-05 |
2015-11-11 |
MicroBPlex, Inc. |
Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
EP3265811B1
(en)
|
2015-03-02 |
2022-10-26 |
Sarcotein Diagnostics LLC |
13+/17+ bin1 expression as a marker of cardiac disorders
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
EP3919507A3
(en)
|
2015-07-01 |
2022-01-12 |
Immatics Biotechnologies GmbH |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
HUE052628T2
(hu)
|
2015-07-06 |
2021-05-28 |
Immatics Biotechnologies Gmbh |
Új peptidek és peptidkombináció a nyelõcsõrák és más ráktípusok elleni immunterápiában történõ használatra
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
CN116375797A
(zh)
|
2016-03-01 |
2023-07-04 |
伊玛提克斯生物技术有限公司 |
用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
|
SG10202008013TA
(en)
|
2016-04-06 |
2020-10-29 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
|
DK3458478T3
(da)
|
2016-05-18 |
2021-03-22 |
Boehringer Ingelheim Int |
Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
|
TW202304970A
(zh)
|
2016-08-26 |
2023-02-01 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
KR20240042177A
(ko)
|
2016-10-05 |
2024-04-01 |
유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 |
Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
EP3559037A1
(en)
|
2016-12-22 |
2019-10-30 |
Wake Forest University Health Sciences |
Sirp-gamma targeted agents for use in the treatment of cancer
|
MA47367B1
(fr)
|
2017-01-27 |
2023-06-28 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
|
GB201701404D0
(en)
|
2017-01-27 |
2017-03-15 |
Micropharm Ltd |
Therapies for treating inflammatory disorders
|
CA3056542A1
(en)
|
2017-03-15 |
2018-09-20 |
Oxford Biomedica (Uk) Limited |
Method
|
DK3600419T5
(en)
|
2017-03-20 |
2023-11-13 |
Vaccinex Inc |
Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
|
ES2963635T3
(es)
|
2017-03-28 |
2024-04-01 |
Ohio State Innovation Foundation |
Vacunas de péptido PD1 humano y usos de las mismas
|
EP3385699A1
(en)
|
2017-04-07 |
2018-10-10 |
Universitat Rovira i Virgili |
Optofluidic device and method for detecting circulating tumour cells
|
WO2018189152A2
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
|
CA3059644A1
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
WO2018189148A1
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
CR20200059A
(es)
|
2017-07-07 |
2020-06-01 |
Immatics Biotechnologies Gmbh |
Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
|
US10800823B2
(en)
|
2017-07-07 |
2020-10-13 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
|
CN110913896A
(zh)
|
2017-07-14 |
2020-03-24 |
弗朗西斯.克里克研究所 |
肿瘤中hla等位基因的分析及其用途
|
US20200209241A1
(en)
|
2017-09-15 |
2020-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
WO2019070108A1
(es)
|
2017-10-02 |
2019-04-11 |
Laboratorios Silanes S.A. De C.V. |
Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
WO2019236590A1
(en)
|
2018-06-04 |
2019-12-12 |
University Of Maryland, Baltimore |
Methods for preventing acute kidney injury
|
CN112638427A
(zh)
|
2018-06-29 |
2021-04-09 |
北卡罗莱纳州立大学 |
用于术后治疗的原位喷雾生物响应性免疫治疗凝胶
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
WO2020115223A1
(en)
|
2018-12-05 |
2020-06-11 |
Katholieke Universiteit Leuven |
S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
WO2020225549A1
(en)
|
2019-05-06 |
2020-11-12 |
The Francis Crick Institute Limited |
Method for preventing inflammation
|
EP3986446A1
(en)
|
2019-06-21 |
2022-04-27 |
Vaccinex, Inc. |
Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
CN114423793A
(zh)
|
2019-09-18 |
2022-04-29 |
分子模板公司 |
包含志贺菌毒素a亚基支架的pd-l1结合分子
|
EP4038222A4
(en)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
|
TW202128756A
(zh)
|
2019-10-02 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
WO2021224687A1
(en)
|
2020-05-08 |
2021-11-11 |
Novocure Gmbh |
Compositions and methods of applying alternating electric fields to pluripotent stem cells
|
AU2021276332A1
(en)
|
2020-05-19 |
2022-11-17 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
EP4232476A2
(en)
|
2020-10-21 |
2023-08-30 |
Boehringer Ingelheim International GmbH |
Agonistic trkb binding molecules for the treatment of eye diseases
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
CN114132883B
(zh)
*
|
2021-11-29 |
2023-12-22 |
义乌市奥飞创意设计有限公司 |
一种可降低气溶胶污染的血清蛋白抑制剂注射装载设备
|
US20240052065A1
(en)
|
2022-07-15 |
2024-02-15 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|